SCHEMBL4397222

SCHEMBL4397222

Fc1cncc(-c2cc(-c3cccc(C(F)(F)F)c3)on2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.53
CYP2C19 P33261 3/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C9 P11712 2/20 0.53
MAOB P27338 2/20 0.47
CXCR1 P25024 1/20 0.46
RAB9A P51151 4/20 0.45
NPC1 O15118 3/20 0.45
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RPS6KB1 P23443 1/20 0.42
IDO1 P14902 1/20 0.41
HSD17B1 P14061 1/20 0.41
HSD17B2 P37059 1/20 0.41
BRD4 O60885 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4329664 0.86 CYP1A2 (0.54) CYP3A4CYP2C19CYP1A2CYP2D6CYP2C9
SCHEMBL4399133 0.84 CYP2C19 (0.67) CYP3A4CYP2C19CYP1A2CYP2D6CYP2C9
SCHEMBL4321601 0.82 NPC1 (0.64) CYP3A4CYP2C19CYP1A2CYP2D6CYP2C9
SCHEMBL4322768 0.82 MAP4K4 (0.46) CYP3A4CYP2C19CYP1A2CYP2D6CYP2C9
SCHEMBL4329713 0.82 RAB9A (0.48) CYP3A4CYP2C19CYP1A2CYP2D6CYP2C9
SCHEMBL4333333 0.80 CYP2C19 (0.53) CYP3A4CYP2C19CYP1A2CYP2D6CYP2C9
SCHEMBL4331562 0.79 CYP3A4 (0.53) CYP3A4CYP2C19CYP1A2CYP2D6CYP2C9
SCHEMBL4456071 0.79 CYP3A4 (0.50) CYP3A4CYP2C19CYP1A2CYP2D6CYP2C9
SCHEMBL4328263 0.78 PTGS2 (0.55) CYP3A4CYP2C19CYP1A2CYP2D6CYP2C9
SCHEMBL4322370 0.77 NPC1 (0.42) CYP3A4CYP2C19CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US claimed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US claimed
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US disclosed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof XDH, PRDX5, CYP4X1 CYP3A4 44/4885CYP2C19 105/4885CYP1A2 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.